Your AI-Trained Oncology Knowledge Connection!
The combination of taselisib and standard letrozole improved the objective response rate compared to letrozole with a placebo in postmenopausal women with estrogen receptor-positive and HER2-negative early breast cancer, according to findings from the LORELEI study presented at the 2017 ESMO Congress in Madrid, Spain.
The PARP inhibitor Rucaparib (Rubraca) improved median progression-free survival by 11.2 months compared with placebo as a maintenance treatment for patients with <em>BRCA</em>-mutant platinum-sensitive ovarian cancer, according to findings from the phase III ARIEL3 trial presented at the 2017 ESMO Congress.
Jonathan Ledermann, MD, professor of medical oncology in the University College London Cancer Institute and director of Cancer Research UK and UCL Cancer Trials Centre, discusses the toxicities associated with rucaparib (Rubraca) for the treatment of ovarian cancer.
The 2017 ESMO Annual Congress, taking place September 8 to 12 in Madrid, Spain, will feature several late-breaking abstracts that are poised to change the future of treatment for patients with lung cancer, pending their results, including the phase III PACIFIC and FLAURA studies.
Omid Hamid, MD, shares the top melanoma abstracts to look out for at the 2017 ESMO Annual Congress, which is taking place September 8 to 12 in Madrid, Spain, as well as some background on the promising phase I/II results he will be presenting for the combination of epacadostat plus pembrolizumab in patients with advanced melanoma.
Lars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses the role of lenvatinib in treating patients with non-small cell lung cancer (NSCLC).
Adding a Toll-like receptor 8 agonist (TLR8) to standard care for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) failed to improve progression-free survival (PFS).
In a recent study, abemaciclib demonstrated clinical activity both alone and in combinations in women with HR+ metastatic breast cancer.
Matthew Galsky, MD, professor of Medicine, Mount Sinai School of Medicine, discusses the significant findings in, and the rationale behind conducting the CheckMate-275 trial during an interview at the 2016 ESMO Congress.
Combined ipilimumab and nivolumab administered pre- and post-surgery reduced the tumor burden in patients with Stage III B/C melanoma, according to first results from the OpACIN trial reported at the ESMO 2016 Annual Congress.
Results of a recent randomized trial showed first-line therapy with nivolumab failed to improve progression-free survival (PFS) in PD-L1–positive non-small cell lung cancer (NSCLC) compared with standard chemotherapy.
Safety, efficacy, and biomarker results from the phase II CheckMate-275 trial of the PD-1 inhibitor nivolumab (Opdivo) that support FDA and European Medicines Agency (EMA) applications were reported at the 2016 ESMO Congress.
Almost 40% of patients with resected early-stage non–small cell lung cancer (NSCLC) had evidence of tumor regression following neoadjuvant treatment with nivolumab (Opdivo) in a preliminary clinical trial.
Cabozantinib (Cabometyx) reduced the risk of progression or death by 31% compared with sunitinib (Sutent) in the frontline setting for patients with metastatic renal cell carcinoma (RCC).
Adjuvant sunitinib (Sutent) prolonged disease-free survival (DFS) by 1.2 years compared with placebo following nephrectomy for patients with high-risk clear cell renal cell carcinoma (RCC).
A technically negative trial in high-risk adult soft tissue sarcoma nonetheless produced a significant survival benefit for anthracycline-based neoadjuvant chemotherapy, according to a study presented at the 2016 ESMO Congress.
Progression-free survival (PFS) was more than 3 times longer with ceritinib (Zykadia) than with chemotherapy, the current second-line standard, in patients with advanced <em>ALK</em>-positive non–small cell lung cancer (NSCLC) who progressed after first-line crizotinib.
Atezolizumab (Tecentriq) reduced the risk of death by 27% compared with docetaxel in patients with advanced non–small cell lung cancer (NSCLC) following the failure of platinum-based chemotherapy.
Lidija Kandolf Sekulovic, MD, PhD, associate professor of Dermatology, Military Medical Academy in Belgrade, Serbia, discusses a recently published survey during an interview at the 2016 ESMO Congress. The survey found that several thousand patients with metastatic melanoma in Europe do not have access to new, life-saving agents in this field.
Mark Kieran, MD, PhD, director, Pediatric Medical Neuro-Oncology, Dana-Farber Cancer Institute, discusses the results of a study that evaluated dabrafenib as a treatment for pediatric patients with BRAF V600-mutant relapsed or refractory low-grade gliomas during an interview at the 2016 ESMO Congress.
Single-agent pembrolizumab (Keytruda) reduced the risk of death by 40% and improved progression-free survival (PFS) by 4.3 months compared with doublet chemotherapy for untreated patients with advanced non–small cell lung cancer (NSCLC) with PD-L1 expression on ≥50% of cells, according to findings from the phase III KEYNOTE-024 trial.
The oral multikinase inhibitor regorafenib (Stivarga) has the potential to become the standard of care as second-line treatment in patients with previously treated hepatocellular carcinoma (HCC) who are unsuitable for loco-regional therapy and have progressed on sorafenib.
Gabriel Hortobagyi, MD, professor of Medicine, University of Texas, MD Anderson Cancer Center, discusses the major findings of the MONALEESA-2 study in advanced breast cancer, during an interview at the 2016 ESMO Congress.
Updated findings from the phase III EORTC 18071 trial show treatment with ipilimumab (Yervoy) reduced the risk of death by 28% versus placebo in patients with high-risk stage III melanoma.
Over one-fourth of patients with metastatic melanoma in Europe do not have access to groundbreaking therapies that could extend their lives, according to a survey presented at the 2016 ESMO Congress.
Mikhail Fedyanin, MD, medical oncologist, Russian Academy of Medical Sciences, Moscow, discusses some of the factors associated with discordance in mutation status in metastatic colorectal cancer during the 2016 ESMO Congress.
Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, discusses the toxicity profile of concurrent nivolumab and ipilimumab as seen in a phase I trial.
Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center, discusses results and key takeaways from the final overall survival (OS) analysis of the CLEOPATRA study.
Patients with unresectable melanoma had a significant improvement in the odds of survival when treated in first line with a combination of BRAF and MEK inhibitors, as opposed to anti-BRAF monotherapy.
Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses the results of a trial that examined AR-V7 and resistance to enzalutamide and abiraterone in patients with prostate cancer.
